Anika Therapeutics, Inc. ANIK
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
6.68
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $112.8M | -$10.9M | $63.8M | $4.4M | $143.5M |
| 2024 | $119.9M | -$56.4M | $76.0M | -$2.3M | $154.0M |
| 2023 | $120.8M | -$82.7M | $82.5M | -$7.2M | $212.3M |
| 2022 | $113.8M | -$14.9M | $73.2M | -$3.1M | $285.6M |
| 2021 | $147.8M | $4.1M | $82.9M | $3.3M | $287.1M |
| 2020 | $130.5M | -$24.0M | $69.0M | $11.4M | $272.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Fischetti Gary P | director | 2026-06-18 | Grant | 10,402 | — |
| HENNEMAN JOHN B III | director | 2026-06-18 | Grant | 10,402 | — |
| Richard Stephen | director | 2026-06-18 | Grant | 10,402 | — |
| Capper Joseph H | director | 2026-06-18 | Grant | 10,402 | — |
| CONLEY SHERYL L | director | 2026-06-18 | Grant | 10,402 | — |
| Griffin Stephen D. | President and CEO | 2026-06-03 | Option exercise | 12,840 | — |
| Griffin Stephen D. | President and CEO | 2026-06-03 | Tax withheld | 3,769 | $14.41 |
| HENNEMAN JOHN B III | director | 2026-05-01 | Buy | 5,000 | $14.66 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.68 (safe)
- Working capital / assets 0.428
- Retained earnings / assets 0.319
- EBIT / assets -0.058
- Equity / liabilities 3.065
Source: SEC EDGAR filings · CIK 0000898437 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.